financetom
Business
financetom
/
Business
/
Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst
Aug 12, 2025 9:21 AM

Shares of Tonix Pharmaceuticals Holding Corp ( TNXP ) are trading sharply higher Tuesday morning following the release of the company’s second-quarter financial results and operational update.

What To Know: The biotechnology company posted a second-quarter net loss of $3.86 per share, which beat the analyst consensus estimate of a $10.73 loss per share. However, sales for the quarter were approximately $2.0 million, missing the estimated $2.6 million.

Despite the mixed top-line results, investors are focusing on the company’s forward-looking catalysts, particularly the upcoming FDA PDUFA goal date of August 15, for its lead drug candidate, TNX-102 SL for fibromyalgia.

Per Tonix, if approved, TNX-102 SL would be the first new medication for the condition in over 16 years, and the company anticipates a potential launch in the fourth quarter of this year.

The optimism is further supported by the company’s solid financial footing. Tonix reported cash and cash equivalents of $125.3 million as of June 30, and expects its current cash runway to fund operations into the third quarter of 2026.

The company also highlighted its recent addition to the Russell 2000 and Russell 3000 Indexes, increasing its visibility to institutional investors.

Benzinga Edge Rankings: According to Benzinga’s Edge stock rankings, which provide four critical scores for stock evaluation, TNXP demonstrates exceptionally strong momentum with a score of 97.16. This high rating suggests significant positive price movement in recent sessions. The stock’s Value score is moderate at 53.01, indicating a neutral valuation profile.

Price Action: According to data from Benzinga Pro, TNXP shares are trading higher by 25.93% to $56.65 Tuesday morning. The stock has a 52-week high of $130.00 and a 52-week low of $6.76.

Read Also: BigBear.AI Stock Is Tumbling Tuesday: Here’s Why

How To Buy TNXP Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Tonix Pharmaceuticals’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone
Nov 24, 2025
08:13 AM EST, 11/24/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that it has earned a $200 million milestone payment from Sarepta Therapeutics ( SRPT ) for meeting a second development milestone event in a phase 1/2 clinical study of ARO-DM1 to treat type 1 myotonic dystrophy. Under the terms of the license and collaboration deal between...
Veeva Systems Expands Partnership With Roche Pharmaceuticals
Veeva Systems Expands Partnership With Roche Pharmaceuticals
Nov 24, 2025
08:12 AM EST, 11/24/2025 (MT Newswires) -- Veeva Systems ( VEEV ) said Monday that Roche Pharmaceuticals has extended its partnership with the company by integrating Veeva Vault CRM, a deep application for life sciences. Financial terms of the expanded partnership were not disclosed. The Vault CRM platform includes Veeva AI, which features industry-specific AI agents, including Free Text Agent,...
Trubar Q3 Revenue Jumps 88%
Trubar Q3 Revenue Jumps 88%
Nov 24, 2025
08:13 AM EST, 11/24/2025 (MT Newswires) -- Trubar ( TRBRF ) said Monday that third-quarter net revenue and adjusted EBITDA both advanced. The company, which manufactures plant-based protein products, said net revenue jumped 88% to US$21.6 million. Adjusted EBITDA rose to $1.4 million from the $1 million in the previous corresponding quarter. Trubar ( TRBRF ) reaffirmed its full year...
X-energy raises $700 million to expand nuclear reactor projects in US
X-energy raises $700 million to expand nuclear reactor projects in US
Nov 24, 2025
Nov 24 (Reuters) - Nuclear reactor developer X-energy said on Monday it had closed a $700 million financing round led by trading company Jane Street to help expand its supply chain and commercial pipeline. WHY IT'S IMPORTANT The U.S. nuclear industry is undergoing a renaissance after years of stagnation, primarily driven by surging power demand from the so-called hyperscalers that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved